82 related articles for article (PubMed ID: 22524679)
1. Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.
Onay-Besikci A; Suzmecelik E; Ozcelikay AT
Can J Physiol Pharmacol; 2012 Aug; 90(8):1087-93. PubMed ID: 22524679
[TBL] [Abstract][Full Text] [Related]
2. Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.
Al-Hesayen A; Azevedo ER; Floras JS; Hollingshead S; Lopaschuk GD; Parker JD
Eur J Heart Fail; 2005 Jun; 7(4):618-23. PubMed ID: 15921803
[TBL] [Abstract][Full Text] [Related]
3. The effects of 2 beta-receptor blocking agents on the microcirculation of healthy subjects and of hypertensive patients.
Albrecht M; Haustein KO
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):580-6. PubMed ID: 9455718
[TBL] [Abstract][Full Text] [Related]
4. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
Feuerstein GZ; Yue TL; Cheng HY; Ruffolo RR
J Hypertens Suppl; 1993 Jun; 11(4):S41-8. PubMed ID: 8104241
[TBL] [Abstract][Full Text] [Related]
5. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K
Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
[TBL] [Abstract][Full Text] [Related]
6. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
Podbregar M; Voga G
J Card Fail; 2002 Dec; 8(6):369-78. PubMed ID: 12528088
[TBL] [Abstract][Full Text] [Related]
7. Influence of beta-adrenoceptor blockade on the myocardial accumulation of fatty acid tracer and its intracellular metabolism in the heart after ischemia-reperfusion injury.
Igarashi N; Nozawa T; Fujii N; Suzuki T; Matsuki A; Nakadate T; Igawa A; Inoue H
Circ J; 2006 Nov; 70(11):1509-14. PubMed ID: 17062979
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of carvedilol and propranolol on glycemic control and insulin resistance associated with L-thyroxin-induced hyperthyroidism--an experimental study.
Bhatt P; Makwana D; Santani D; Goyal R
Can J Physiol Pharmacol; 2007 May; 85(5):514-20. PubMed ID: 17632586
[TBL] [Abstract][Full Text] [Related]
9. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Lainscak M; Podbregar M; Kovacic D; Rozman J; von Haehling S
Respir Med; 2011 Oct; 105 Suppl 1():S44-9. PubMed ID: 22015086
[TBL] [Abstract][Full Text] [Related]
10. Adrenergic blockade reduces skeletal muscle glycolysis and Na(+), K(+)-ATPase activity during hemorrhage.
McCarter FD; James JH; Luchette FA; Wang L; Friend LA; King JK; Evans JM; George MA; Fischer JE
J Surg Res; 2001 Aug; 99(2):235-44. PubMed ID: 11469892
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers.
Gasser JA; Betterridge DJ
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S29-34. PubMed ID: 1721976
[TBL] [Abstract][Full Text] [Related]
12. Interaction of beta-blockers with the renal uptake transporter OCT2.
Bachmakov I; Glaeser H; Endress B; Mörl F; König J; Fromm MF
Diabetes Obes Metab; 2009 Nov; 11(11):1080-3. PubMed ID: 19740083
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes.
Kurosaki K; Ikeda U; Maeda Y; Shimada K
J Mol Cell Cardiol; 2000 Feb; 32(2):333-9. PubMed ID: 10722808
[TBL] [Abstract][Full Text] [Related]
14. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats.
Barone FC; Nelson AH; Ohlstein EH; Willette RN; Sealey JE; Laragh JH; Campbell WG; Feuerstein GZ
J Pharmacol Exp Ther; 1996 Nov; 279(2):948-55. PubMed ID: 8930204
[TBL] [Abstract][Full Text] [Related]
15. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells.
Yue TL; Wang X; Gu JL; Ruffolo RR; Feuerstein GZ
J Pharmacol Exp Ther; 1995 Jun; 273(3):1442-9. PubMed ID: 7791119
[TBL] [Abstract][Full Text] [Related]
16. Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade.
Grimm D; Huber M; Jabusch HC; Shakibaei M; Fredersdorf S; Paul M; Riegger GA; Kromer EP
J Mol Cell Cardiol; 2001 Mar; 33(3):487-501. PubMed ID: 11181017
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.
Willette RN; Aiyar N; Yue TL; Mitchell MP; Disa J; Storer BL; Naselsky DP; Stadel JM; Ohlstein EH; Ruffolo RR
J Pharmacol Exp Ther; 1999 Apr; 289(1):48-53. PubMed ID: 10086986
[TBL] [Abstract][Full Text] [Related]
18. A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
Takahama H; Asanuma H; Sanada S; Fujita M; Sasaki H; Wakeno M; Kim J; Asakura M; Takashima S; Minamino T; Komamura K; Sugimachi M; Kitakaze M
Basic Res Cardiol; 2010 Nov; 105(6):787-94. PubMed ID: 20852875
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.
Jacob S; Rett K; Wicklmayr M; Agrawal B; Augustin HJ; Dietze GJ
J Hypertens; 1996 Apr; 14(4):489-94. PubMed ID: 8761899
[TBL] [Abstract][Full Text] [Related]
20. Effects of adrenoceptor blocking drugs on cardiovascular responsiveness to passive orthostasis: a placebo-controlled double-blind study.
Nieminen T; Ylitalo R; Kööbi T; Ylitalo P; Kähönen M
Arzneimittelforschung; 2005; 55(4):205-11. PubMed ID: 15901043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
